Welcome, Guest. Please login or register.
December 04, 2020, 06:17:12 am

Login with username, password and session length

  • Total Posts: 55052
  • Total Topics: 4816
  • Online Today: 55
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 36
Total: 36


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Aramchol Lowers Liver Fat in Those With Fatty Liver Disease  (Read 5580 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 772
    • Hep Mag
Aramchol Lowers Liver Fat in Those With Fatty Liver Disease
« on: January 14, 2019, 10:36:22 am »
In a recent trial, Galmed Pharmaceuticals’ Aramchol showed promise in reducing liver fat among those with non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, Healio reports.

Presenting their findings at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco (The Liver Meeting), researchers conducted a Phase IIb trial of Aramchol treatment among 247 people who had NASH according to a biopsy. These individuals were also overweight or obese and had prediabetes or diabetes.

For more...


© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.